Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients

Wen-Chin Ko, Cheuk-Sing Choy, Wei-Ning Lin, Shu-Wei Chang, Jian-Chiun Liou, Tao-Hsin Tung, Chih-Yu Hsieh, Jia-Feng Chang

研究成果: 雜誌貢獻文章

摘要

Background: Interactions and joint effects of galectin-3 and vascular cell adhesion molecule 1 (VCAM-1) on risks of all-cause and cardiovascular (CV) mortality remain unclear in patients with maintenance hemodialysis (MHD). Methods: Unadjusted and adjusted hazard ratios (aHRs) of mortality risks were analyzed between higher and lower concentration groups of serum galectin-3 and VCAM-1. The modification effect between serum galectin-3 and VCAM-1 on mortality risk was investigated using an interaction product term. Results: During follow-up, galectin-3 and VCAM-1 were associated with incremental risks of all-cause mortality (aHR: 1.038 (95% confidence interval (CI): 1.001–1.077) and 1.002 (95% CI: 1.001–1.003), respectively). Nonetheless, VCAM-1 but not galectin-3 predicted CV mortality (aHR: 1.043 (95% CI: 0.993–1.096) and 1.002 (95% CI: 1.001–1.003), respectively). In the interaction analysis, patients with combined higher galectin-3 (>29.5 ng/mL) and VCAM-1 (>1546.9 ng/mL) were at the greatest risk of all-cause and CV mortality (aHR: 4.6 (95% CI: 1.6–13.4), and 4.2 (95% CI: 1.3–14.4), respectively). The interactions between galectin-3 and VCAM-1 with respect to all-cause and CV mortality were statistically significant (p < 0.01 and < 0.05, respectively). Conclusion: Galectin-3 and VCAM-1 could serve as a promising dual biomarker for prognostic assessment, considering their joint effects on pathogenesis of leukocyte trafficking and atherothrombosis
原文英語
期刊Journal of Clinical Medicine
7
發行號10
DOIs
出版狀態已發佈 - 九月 24 2018

指紋

Galectin 3
Vascular Cell Adhesion Molecule-1
Renal Dialysis
Mortality
Confidence Intervals
Serum
Leukocytes
Biomarkers
Odds Ratio
Maintenance

Keywords

  • galectin
  • cell adhesion molecules
  • mortality
  • hemodialysis

引用此文

Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients. / Ko, Wen-Chin; Choy, Cheuk-Sing; Lin, Wei-Ning; Chang, Shu-Wei; Liou, Jian-Chiun; Tung, Tao-Hsin; Hsieh, Chih-Yu; Chang, Jia-Feng.

於: Journal of Clinical Medicine, 卷 7, 編號 10, 24.09.2018.

研究成果: 雜誌貢獻文章

Ko, Wen-Chin ; Choy, Cheuk-Sing ; Lin, Wei-Ning ; Chang, Shu-Wei ; Liou, Jian-Chiun ; Tung, Tao-Hsin ; Hsieh, Chih-Yu ; Chang, Jia-Feng. / Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients. 於: Journal of Clinical Medicine. 2018 ; 卷 7, 編號 10.
@article{4e5d5ca4a6ca4be7b7613a837999237a,
title = "Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients",
abstract = "BACKGROUND: Interactions and joint effects of galectin-3 and vascular cell adhesion molecule 1 (VCAM-1) on risks of all-cause and cardiovascular (CV) mortality remain unclear in patients with maintenance hemodialysis (MHD).METHODS: Unadjusted and adjusted hazard ratios (aHRs) of mortality risks were analyzed between higher and lower concentration groups of serum galectin-3 and VCAM-1. The modification effect between serum galectin-3 and VCAM-1 on mortality risk was investigated using an interaction product term.RESULTS: During follow-up, galectin-3 and VCAM-1 were associated with incremental risks of all-cause mortality (aHR: 1.038 (95{\%} confidence interval (CI): 1.001⁻1.077) and 1.002 (95{\%} CI: 1.001⁻1.003), respectively). Nonetheless, VCAM-1 but not galectin-3 predicted CV mortality (aHR: 1.043 (95{\%} CI: 0.993⁻1.096) and 1.002 (95{\%} CI: 1.001⁻1.003), respectively). In the interaction analysis, patients with combined higher galectin-3 (>29.5 ng/mL) and VCAM-1 (>1546.9 ng/mL) were at the greatest risk of all-cause and CV mortality (aHR: 4.6 (95{\%} CI: 1.6⁻13.4), and 4.2 (95{\%} CI: 1.3⁻14.4), respectively). The interactions between galectin-3 and VCAM-1 with respect to all-cause and CV mortality were statistically significant (p < 0.01 and < 0.05, respectively).CONCLUSION: Galectin-3 and VCAM-1 could serve as a promising dual biomarker for prognostic assessment, considering their joint effects on pathogenesis of leukocyte trafficking and atherothrombosis.",
keywords = "galectin, cell adhesion molecules, mortality, hemodialysis",
author = "Wen-Chin Ko and Cheuk-Sing Choy and Wei-Ning Lin and Shu-Wei Chang and Jian-Chiun Liou and Tao-Hsin Tung and Chih-Yu Hsieh and Jia-Feng Chang",
year = "2018",
month = "9",
day = "24",
doi = "10.3390/jcm7100300",
language = "English",
volume = "7",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients

AU - Ko, Wen-Chin

AU - Choy, Cheuk-Sing

AU - Lin, Wei-Ning

AU - Chang, Shu-Wei

AU - Liou, Jian-Chiun

AU - Tung, Tao-Hsin

AU - Hsieh, Chih-Yu

AU - Chang, Jia-Feng

PY - 2018/9/24

Y1 - 2018/9/24

N2 - BACKGROUND: Interactions and joint effects of galectin-3 and vascular cell adhesion molecule 1 (VCAM-1) on risks of all-cause and cardiovascular (CV) mortality remain unclear in patients with maintenance hemodialysis (MHD).METHODS: Unadjusted and adjusted hazard ratios (aHRs) of mortality risks were analyzed between higher and lower concentration groups of serum galectin-3 and VCAM-1. The modification effect between serum galectin-3 and VCAM-1 on mortality risk was investigated using an interaction product term.RESULTS: During follow-up, galectin-3 and VCAM-1 were associated with incremental risks of all-cause mortality (aHR: 1.038 (95% confidence interval (CI): 1.001⁻1.077) and 1.002 (95% CI: 1.001⁻1.003), respectively). Nonetheless, VCAM-1 but not galectin-3 predicted CV mortality (aHR: 1.043 (95% CI: 0.993⁻1.096) and 1.002 (95% CI: 1.001⁻1.003), respectively). In the interaction analysis, patients with combined higher galectin-3 (>29.5 ng/mL) and VCAM-1 (>1546.9 ng/mL) were at the greatest risk of all-cause and CV mortality (aHR: 4.6 (95% CI: 1.6⁻13.4), and 4.2 (95% CI: 1.3⁻14.4), respectively). The interactions between galectin-3 and VCAM-1 with respect to all-cause and CV mortality were statistically significant (p < 0.01 and < 0.05, respectively).CONCLUSION: Galectin-3 and VCAM-1 could serve as a promising dual biomarker for prognostic assessment, considering their joint effects on pathogenesis of leukocyte trafficking and atherothrombosis.

AB - BACKGROUND: Interactions and joint effects of galectin-3 and vascular cell adhesion molecule 1 (VCAM-1) on risks of all-cause and cardiovascular (CV) mortality remain unclear in patients with maintenance hemodialysis (MHD).METHODS: Unadjusted and adjusted hazard ratios (aHRs) of mortality risks were analyzed between higher and lower concentration groups of serum galectin-3 and VCAM-1. The modification effect between serum galectin-3 and VCAM-1 on mortality risk was investigated using an interaction product term.RESULTS: During follow-up, galectin-3 and VCAM-1 were associated with incremental risks of all-cause mortality (aHR: 1.038 (95% confidence interval (CI): 1.001⁻1.077) and 1.002 (95% CI: 1.001⁻1.003), respectively). Nonetheless, VCAM-1 but not galectin-3 predicted CV mortality (aHR: 1.043 (95% CI: 0.993⁻1.096) and 1.002 (95% CI: 1.001⁻1.003), respectively). In the interaction analysis, patients with combined higher galectin-3 (>29.5 ng/mL) and VCAM-1 (>1546.9 ng/mL) were at the greatest risk of all-cause and CV mortality (aHR: 4.6 (95% CI: 1.6⁻13.4), and 4.2 (95% CI: 1.3⁻14.4), respectively). The interactions between galectin-3 and VCAM-1 with respect to all-cause and CV mortality were statistically significant (p < 0.01 and < 0.05, respectively).CONCLUSION: Galectin-3 and VCAM-1 could serve as a promising dual biomarker for prognostic assessment, considering their joint effects on pathogenesis of leukocyte trafficking and atherothrombosis.

KW - galectin

KW - cell adhesion molecules

KW - mortality

KW - hemodialysis

U2 - 10.3390/jcm7100300

DO - 10.3390/jcm7100300

M3 - Article

C2 - 30249969

VL - 7

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 10

ER -